CoChat

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Open access
Oppermann, Sina, Ylanko, Jarkko, Shi, Yonghong, Hariharan, Santosh, Oakes, Christopher C., Brauer, Patrick M., Zúñiga-Pflücker, Juan C., Leber, Brian, Spaner, David E., Andrews, David W. · 2016 · Blood
Cited by 122

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Key Points: Patient-specific pathways of resistance to venetoclax can be identified by high-content screening of clinical samples with a KI library. Sunitinib may overcome resistance to venetoclax for many patients by downregulating the expression of Bcl-xl, Mcl-1, and A1 in CLL cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-12-687814

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 71

  1. Meads, 2008, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance., Clin Cancer Res, 14, 2519, 10.1158/1078-0432.CCR-07-2223 · DOI · Paper page
  2. Burger, 2000, Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1., Blood, 96, 2655, 10.1182/blood.V96.8.2655 · DOI · Paper page
  3. Kurtova, 2009, Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance., Blood, 114, 4441, 10.1182/blood-2009-07-233718 · DOI · Paper page
  4. Vogler, 2009, Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia., Blood, 113, 4403, 10.1182/blood-2008-08-173310 · DOI · Paper page
  5. Brahmbhatt, 2015, Molecular pathways: leveraging the BCL-2 interactome to kill cancer cells--mitochondrial outer membrane permeabilization and beyond., Clin Cancer Res, 21, 2671, 10.1158/1078-0432.CCR-14-0959 · DOI
  6. Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2 [published correction appears in Proc Natl Acad Sci USA. 2006;103(7):2464]., Proc Natl Acad Sci USA, 102, 13944, 10.1073/pnas.0506654102 · DOI · Paper page
  7. Smit, 2007, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity., Blood, 109, 1660, 10.1182/blood-2006-05-021683 · DOI · Paper page
  8. Anderson, 2016, The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism., Blood, 127, 3215, 10.1182/blood-2016-01-688796 · DOI · Paper page
  9. Roberts, 2016, Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia., N Engl J Med, 374, 311, 10.1056/NEJMoa1513257 · DOI · Paper page
  10. Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets., Nat Med, 19, 202, 10.1038/nm.3048 · DOI · Paper page
  11. Spaner, 2013, PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia., Leukemia, 27, 1090, 10.1038/leu.2012.329 · DOI
  12. Tomic, 2006, Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity., J Immunol, 176, 3830, 10.4049/jimmunol.176.6.3830 · DOI
  13. Spaner, 2006, Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells., Leukemia, 20, 286, 10.1038/sj.leu.2404061 · DOI
  14. Shen, 2013, Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs [published correction appears at http://dx.doi.org/10.1371/annotation/e2536fcb-3ab3-44a0-8eab-91aaeb8e49b6]., PLoS One, 8, e75252, 10.1371/journal.pone.0075252 · DOI
  15. Thijssen, 2015, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors., Haematologica, 100, e302
  16. Crassini, 2015, The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine., Leuk Lymphoma, 56, 3407, 10.3109/10428194.2015.1032963 · doi:10.3109/10428194.2015.1032963
  17. Crassini, 2015, Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: a review of the in vitro and clinical trials to date., World J Clin Cases, 3, 694, 10.12998/wjcc.v3.i8.694 · DOI
  18. Li, 2015, Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A., Blood, 126, 766, 10.1182/blood-2014-12-618678 · DOI
  19. Lessene, 2008, BCL-2 family antagonists for cancer therapy., Nat Rev Drug Discov, 7, 989, 10.1038/nrd2658 · DOI · Paper page
  20. Kepp, 2011, Cell death assays for drug discovery., Nat Rev Drug Discov, 10, 221, 10.1038/nrd3373 · DOI · Paper page
  21. Collins, 2015, A versatile cell death screening assay using dye-stained cells and multivariate image analysis., Assay Drug Dev Technol, 13, 547, 10.1089/adt.2015.661 · DOI
  22. Douglas, 1997, Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta., Blood, 89, 941, 10.1182/blood.V89.3.941 · DOI
  23. Panayiotidis, 1993, Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro., Br J Haematol, 85, 439, 10.1111/j.1365-2141.1993.tb03330.x · DOI · Paper page
  24. Steele, 2010, The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment., Blood, 116, 4569, 10.1182/blood-2009-09-245811 · DOI
  25. de Totero, 1999, IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia., Br J Haematol, 104, 589, 10.1046/j.1365-2141.1999.01219.x · DOI
  26. Kay, 2001, Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis., Br J Haematol, 112, 760, 10.1046/j.1365-2141.2001.02605.x · doi:10.1046/j.1365-2141.2001.02605.x
  27. Rossmann, 2002, Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)., Eur J Haematol, 68, 299, 10.1034/j.1600-0609.2002.01612.x · doi:10.1034/j.1600-0609.2002.01612.x
  28. Chow, 2007, Sunitinib: from rational design to clinical efficacy., J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602 · DOI · Paper page
  29. Christensen, 2007, A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities., Ann Oncol, 18, x3, 10.1093/annonc/mdm408 · DOI
  30. Ebos, 2007, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy., Proc Natl Acad Sci USA, 104, 17069, 10.1073/pnas.0708148104 · DOI · Paper page
  31. Henderson, 2015, A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib., eLife, 4, e08351, 10.7554/eLife.08351 · DOI · Paper page
  32. Shanafelt, 2010, Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia., Leuk Lymphoma, 51, 2222, 10.3109/10428194.2010.524327 · doi:10.3109/10428194.2010.524327
  33. Claus, 2012, A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR., Epigenetics, 7, 772, 10.4161/epi.20299 · DOI · Paper page
  34. Kröber, 2002, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia., Blood, 100, 1410, 10.1182/blood.V100.4.1410.h81602001410_1410_1416 · DOI · Paper page
  35. Mertens, 2014, Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?, J Clin Oncol, 32, 869, 10.1200/JCO.2013.53.8421 · DOI
  36. Oakes, 2016, DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia., Nat Genet, 48, 253, 10.1038/ng.3488 · DOI · Paper page
  37. Queirós, 2015, A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact., Leukemia, 29, 598, 10.1038/leu.2014.252 · DOI · Paper page
  38. Longo, 2008, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells., Blood, 111, 846, 10.1182/blood-2007-05-089037 · DOI · Paper page
  39. Purroy, 2014, Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein., Leukemia, 28, 1993, 10.1038/leu.2014.96 · DOI
  40. Néron, 1996, Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand., Immunol Invest, 25, 79, 10.3109/08820139609059292 · doi:10.3109/08820139609059292
  41. Soderquist, 2013, Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo., Leukemia, 27, 2262, 10.1038/leu.2013.138 · doi:10.1038/leu.2013.138
  42. Willimott, 2007, CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia., Br J Haematol, 138, 721, 10.1111/j.1365-2141.2007.06717.x · DOI
  43. Willimott, 2007, Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4., Haematologica, 92, 1359, 10.3324/haematol.11340 · doi:10.3324/haematol.11340
  44. Brown, 2014, Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia., Blood, 123, 3390, 10.1182/blood-2013-11-535047 · DOI · Paper page
  45. Woyach, 2015, Targeted therapies in CLL: mechanisms of resistance and strategies for management., Blood, 126, 471, 10.1182/blood-2015-03-585075 · DOI
  46. Del Gaizo Moore, 2007, Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737., J Clin Invest, 117, 112, 10.1172/JCI28281 · DOI · Paper page
  47. Tromp, 2010, Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering., Oncogene, 29, 5071, 10.1038/onc.2010.248 · DOI
  48. Davids, 2012, Targeting the B cell receptor pathway in chronic lymphocytic leukemia., Leuk Lymphoma, 53, 2362, 10.3109/10428194.2012.695781 · DOI
  49. Herishanu, 2011, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia., Blood, 117, 563, 10.1182/blood-2010-05-284984 · DOI · Paper page
  50. Rahmani, 2012, Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process., Blood, 119, 6089, 10.1182/blood-2011-09-378141 · DOI
  51. Abrams, 2003, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer., Mol Cancer Ther, 2, 1011
  52. Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer., Mol Cancer Ther, 2, 471
  53. Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin Cancer Res, 9, 327
  54. Murray, 2003, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model., Clin Exp Metastasis, 20, 757, 10.1023/B:CLIN.0000006873.65590.68 · DOI · Paper page
  55. O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo., Blood, 101, 3597, 10.1182/blood-2002-07-2307 · DOI · Paper page
  56. Kaefer, 2014, Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia., Cancer Chemother Pharmacol, 74, 593, 10.1007/s00280-014-2530-9 · DOI · Paper page
  57. Roberts, 2012, Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease., J Clin Oncol, 30, 488, 10.1200/JCO.2011.34.7898 · DOI · Paper page
  58. Cervantes-Gomez, 2015, Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia., Clin Cancer Res, 21, 3705, 10.1158/1078-0432.CCR-14-2809 · DOI · Paper page
  59. O’Brien, 2014, Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial., Lancet Oncol, 15, 48, 10.1016/S1470-2045(13)70513-8 · DOI · Paper page
  60. Martinez Marignac, 2013, Resistance to dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming., Oncotarget, 4, 2550, 10.18632/oncotarget.1508 · DOI
  61. Pitini, 2011, The role of p53 and autophagy in dasatinib resistance of CLL lymphocytes., Leuk Res, 35, 32, 10.1016/j.leukres.2010.07.007 · doi:10.1016/j.leukres.2010.07.007
  62. Amrein, 2011, The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms., Leuk Lymphoma, 52, 754, 10.3109/10428194.2011.555890 · DOI
  63. Amrein, 2011, Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia., Clin Cancer Res, 17, 2977, 10.1158/1078-0432.CCR-10-2879 · DOI · Paper page
  64. Eley, 2009, Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects., J Clin Pharmacol, 49, 700, 10.1177/0091270009333854 · DOI
  65. Hussain, 2008, Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium., Blood, 111, 3190, 10.1182/blood-2007-10-115733 · DOI
  66. Lin, 2008, Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies., Clin Lymphoma Myeloma, 8, S137, 10.3816/CLM.2008.s.009 · DOI
  67. Lanasa, 2015, Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia., Leuk Res, 39, 495, 10.1016/j.leukres.2015.02.001 · DOI
  68. Goodman, 2007, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma., Clin Cancer Res, 13, 1367, 10.1158/1078-0432.CCR-06-2328 · DOI · Paper page
  69. Kronabel, 2015, Possible influence of some foods on the metabolism of ibrutinib., Clin Lab, 61, 443
  70. Rais, 2012, Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study., Biomed Chromatogr, 26, 1315, 10.1002/bmc.2697 · DOI
  71. Weiss, 2016, Venetoclax (ABT-199) might act as a perpetrator in pharmacokinetic drug-drug interactions., Pharmaceutics, 8, 10.3390/pharmaceutics8010005 · DOI

Cited by

See all 122

Metadata

Authors
Oppermann, S., Ylanko, J., Shi, Y., Hariharan, S., Oakes, C. C., Brauer, P. M., Zúñiga-Pflücker, J. C., Leber, B., Spaner, D. E., & Andrews, D. W.
Venue
Blood
Published
2016-08-18
Volume
128
Issue
7
Pages
934-947
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2510710599
Cited by
122
References
8
FWCI
8.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. https://app.cochat.ai/papers/10.1182/blood-2015-12-687814
The paper
Oppermann, S., Ylanko, J., Shi, Y., Hariharan, S., Oakes, C. C., Brauer, P. M., Zúñiga-Pflücker, J. C., Leber, B., Spaner, D. E., & Andrews, D. W. (2016). High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. https://doi.org/10.1182/blood-2015-12-687814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.